Carmela Colangelo
Potenza, 85100, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Elexacaftor/Tezacaftor/Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation and Advanced Lung Disease: A 48-Week Observational Study.
Journal: Journal of clinical medicine
Published: December 20, 2021
Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype.
Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society
Published: December 09, 2021
Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis Patients with The F508del/Unknown Genotype.
Journal: Antibiotics (Basel, Switzerland)
Published: May 28, 2021
Effectiveness and safety of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease with the Phe508del/minimal function genotype.
Journal: Respiratory medicine
Published: May 04, 2021
Effectivenesss of ivacaftor in severe cystic fibrosis patients and non-G551D gating mutations.
Journal: Pediatric pulmonology
Published: April 09, 2019
Salt depletion syndrome as the initial presentation of cystic fibrosis in a toddler with the rare p.Ala309Gly (A309G) CFTR variant.
Journal: Clinical genetics
Published: October 15, 2015
p.Leu636Pro mutation is associated with cystic fibrosis transmembrane conductance regulator-related disorders (congenital bilateral absence of vas deferens).
Journal: International journal of urology : official journal of the Japanese Urological Association
Published: January 21, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026